Guidelines for antiretroviral therapy for HIV infection

CMAJ. Canadian Medical Association Journal

Volumn 158, Issue 4, 1998, Pages 496-505

  Rachlis, Anita R ^b   Zarowny, Donald P ^a  

^a ST PAUL S HOSPITAL   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; BILIRUBIN; CD4 ANTIGEN; DELAVIRDINE; DIDANOSINE; GELATIN; INDINAVIR; LAMIVUDINE; LIPID; LIVER ENZYME; NELFINAVIR; NEVIRAPINE; NUCLEOSIDE ANALOG; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ADULT; ANEMIA; APHTHOUS STOMATITIS; BILIRUBIN BLOOD LEVEL; CANADA; CHILD; DIARRHEA; DIGESTIVE SYSTEM FUNCTION DISORDER; DISEASE MARKER; DRUG CHOICE; DRUG INTERACTION; FATTY LIVER; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSOMNIA; LACTIC ACIDOSIS; LIPID BLOOD LEVEL; LIVER DYSFUNCTION; MYOPATHY; NAUSEA; NEPHROLITHIASIS; NEUTROPENIA; PANCREATITIS; PARESTHESIA; PERIPHERAL NEUROPATHY; PRACTICE GUIDELINE; PRIMARY INFECTION; PROPHYLAXIS; RASH; REVIEW; TASTE DISORDER; VERTICAL TRANSMISSION; VIRUS LOAD;

EID: 0032562117     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: None     Document Type: Review

References (55)

1. Mellors JW, Kingsley LA, Rinaldo CR Jr, Todd JA, Hoo BS, Kokka RP, et al. Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Intern Med 1995;122(8):573-9.
2. Mellors JW, Rinaldo CR Jr, Gupta P, White RM, Todd JA, Kingsley LA. Prognosis in HIV-1 infection predicted by the quantify of virus in plasma. Science 1996;272:1167-70.
3. O'Brien WA, Hartigan PM, Martin D, Esinhart J, Hill A, Benoit S, et al. Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. N Engl J Med 1996;334:426-31.
4. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 1996;271:1582-6.
5. Coffin JM. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 1995;267:483-9.
6. Carpenter CC, Fischl MA, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein DA, et al. Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. International AIDS Society-USA. JAMA 1996;276:146-54.
7. Katzenstein DA, Hammer SM, Hughes MD, Gundacker H, Jackson JB, Fiscus S, et al. The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. N Engl J Med 1996;335:1091-8.
8. Saag MS, Holodniy M, Kuritzkes DR, O'Brien WA, Coombs R, Poscher ME, et al. HIV viral load markers in clinical practice. Nat Med 1996;2(6):625-9.
9. Staprans SI, Hamilton BL, Follansbee SE, Elbeik T, Barbosa P, Grant RM, et al. Activation of virus replication after vaccination of HIV-1 infected individuals. J Exp Med 1995;182(6):1727-37.
10. O'Brien WA, Grovit-Ferbas K, Namazi A, Ovcak-Derzic S, Wang HJ, Park J, et al. Human immunodeficiency virus-type 1 replication can be increased in peripheral blood of seropositive patients after influenza vaccination. Blood 1995;86(3):1082-9.
11. Coffin JM. HIV viral dynamics. AIDS 1996;10(suppl 3):S75-S84.
12. Richman DD. Resistance of clinical isolates of human immunodeficiency virus to antiretroviral agents. Antimicrob Agents Chemother 1993;37:1207-13.
13. Jacobsen H, Hanggi M, Ott M, Duncan IB, Owen S, Andreoni M, et al. In vivo resistance to a human immunodeficiency virus type 1 protease inhibitor: mutations, kinetics and frequencies. J Infect Dis 1996;173(6):1379-87.
14. Condra JH, Schleif WA, Blahy OM, Gabryelski LJ, Graham DJ, Quintero JC, et al. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 1995;374:569-71.
15. Blaschke TF. Noncompliance and resistance to protease inhibitors [abstract a43]. 4th Conference on Retroviruses and Opportunistic Infections; 1997 Jan 22-26; Washington.
16. Ho DD. Time to hit HIV, early and hard. N Engl J Med 1995;333:450-1.
17. Markowitz M, Cao Y, Hurley A, O'Donovan R, Heath-Chiozzi M, Leonard J, et al. Triple therapy with AZT, 3TC and ritonavir in 12 subjects newly infected with HIV [abstract Th.B.933.]. XI International Conference on AIDS; 1996 July 7-12; Vancouver.
18. Lafeuillade A, Poggi C, Tamalet C, Profizi N, Tourres C, Costes O. Effects of a combination of zidovudine, didanosine and lamivudine on primary human immunodeficiency vims type 1 infection. J Infect Dis 1997;175(5):1051-5.
19. Hammer SM, Katzenstein DA, Hughes MD, Gundacker H, Schooley RT, Haubrich RH, et al. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. N Engl J Med 1996;335:1081-90.
20. Saravolatz LD, Winslow DL, Collins G, Hodges JS, Pettinelli C, Stein DS, et al. Zidovudine alone or in combination with didanosine or zalcitabine in HIV-infected patients with the acquired immunodeficiency syndrome or fewer than 200 CD4 cells per cubic millimeter. N Engl J Med 1996;335:1099-106.
21. DELTA Coordinating Committee. DELTA: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Lancet 1996;348:283-91.
22. Eron JJ, Benoit SL, Jemsek J, MacArthur RD, Santana J, Quinn JB, et al. Treatment with lamivudine, zidovudine or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. N Engl J Med 1995;333:1662-9.
23. Staszewski S, Hill AM, Bartlett J, Eron JJ, Katlama C, Johnson J, et al. Reduction in HIV-1 disease progression for zidovudine/lamivudine relative to control treatments: a meta-analysis of controlled trials. AIDS 1997;11(4):477-83.
24. Myers MW, Montaner JSG, INCAS Study Group. A randomized, double-blinded comparative trial of the effects of zidovudine, didanosine and nevirapine combinations in antiviral naive, AIDS-free, HIV-infected patients with CD4 counts 200-600/mm3 [abstract Mo.B.294]. XI International Conference on AIDS; 1996 Jul 7-12; Vancouver.
25. Gulick RM, Mellors J, Havlir D, Eron J, Gonzalez C, McMahon D, et al. Potent and sustained antiretroviral activity of indinavir (IDV), zidovudine (ZDV) and lamivudine (3TC) [abstract Th.B. 931]. XI International Conference on AIDS; 1996 Jul 7-12; Vancouver.
26. CAESAR Coordinating Committee. Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: the CAESAR trial. Lancet 1997;349:1413-21.
27. Freimuth WW, Chuang-Stein CJ, Greenwald CA, Wathen LK, Edge-Padbury BA, Cox SR, et al. Delavirdine (DLV) combined with zidovudine (ZDV) or didanosine (DDI) produces sustained reduction in viral burden and increases in CD4 count in early and advanced HIV-1 infection [abstract Mo.B.295). XI International Conference on AIDS; 1996 July 7-12; Vancouver.
28. D'Aquila RT, Hughes MD, Johnson VA, Fischl MA, Sommadossi JP, Liou SH, et al. Nevirapine, zidovudine and didanosine compared with zidovudine and didanosine in patients with HIV-I infection. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1996;124:1019-30.
29. Collier AC, Coombs RW, Schoenfeld DA, Bassett RL, Timpone J, Baruch A, et al. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. N Engl J Med 1996;334:1011-8.
30. Mathez D, de Truchis P, Gorin I, Katlama C, Pialoux G, Saimot AG, et al. Ritonavir, AZT, DDC, as a triple combination in AIDS patients [abstract 285]. 3rd Conference on Retroviruses and Opportunistic Infections; 1996 Jan 28-Feb 1; Washington.
31. Cameron W, Sun E, Markowitz M, Farthing C, McMahon D, Poretz D, et al. Combination use of ritonavir and saquinavir in HIV-infected patients: preliminary safety and activity data [abstract Th.B. 934]. XI International Conference on AIDS; 1996 Jul 7-12; Vancouver.
32. Cameron DW, Heath-Chiozzi M, Kravcik S, Mills R, Potthoff A, Henry D. Prolongation of life and prevention of AIDS complications in advanced HIV immunodeficiency with ritonavir: update (abstract Mo.B.411]. XI International Conference on AIDS; 1996 Jul 7-12; Vancouver.
33. Lalezari J, Haubrich R, Burger NH, Beattie D, Donatacci L, Salgo MP, et al. Improved survival and decreased progression of HIV in patients treated with saquinavir (Invirase, SQV) plus HIVID (zalcitabine, ddC) [abstract LB.B.6033]. XI International Conference on AIDS; 1996 Jul 7-12; Vancouver.
34. Study confirms that combination treatment using a protease inhibitor can delay HIV disease progression and death [press release]. Bethesda (MD): National Institutes of Health; 1997 Feb 25.
35. US Centers for Disease Control and Prevention. 1994 revised classification system for human immunodeficiency virus infection in children less than 13 years of age. MMWR 1994;43(RR-12):1-10.
36. Foudraine N, deWolf F, Hoetelmans R, Portegies P, Maas J, Lange J. CSF and serum HIV-RNA levels during AZT/3TC and d4T/3TC treatment [abstract LB5], 4th Conference on Retroviruses and Opportunistic Infections; 1997 Jan 22-26; Washington.
37. Gisslen M, Norkrans G, Svennerholm B, Hagberg L. The effect of human immunodeficiency virus type 1 RNA levels in cerebrospinal fluid after initiation of zidovudine or didanosine. J Infect Dis 1997;175:434-7.
38. Kravcik S, Sahai J, Kerr B, Anderson R, Buss N, Seguin I, et al. Nelfinavir mesylate (NVF) increases saquinavir-soft gel capsule (SQV-SGC) exposure in HIV+ patients [abstract 371], 4th Conference on Retroviruses and Opportunistic Infections; 1997 Jan 22-26; Washington.
39. Pollard R, Peterson D, Hardy D, Pedneault L, Rutkiewicz V, Pottage J, et al. Stavudine (d4T) and didanosine (ddI) combination therapy in HIV-infected subjects: antiviral effect and safety in an ongoing pilot randomized double-blinded trial [abstract Th.B.293]. XI International Conference on AIDS; 1996 Jul 7-12; Vancouver.
40. Connor EM, Sperling RS, Gelber R, Kiselev P, Scott G, O'Sullivan MJ, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med 1994;331:1173-80.
41. Mirochnick M, Sullivan J, Gagnier P, Fenton T, Sperling R, ACTG Protocol 250 Team. Safety and pharmacokinetics (PK) of nevirapine (NVP) in neonates born to HIV-1 infected women [abstract 723]. 4th Conference on Retroviruses and Opportunistic Infections; 1997 Jan 22-26; Washington.
42. Englund JA, Baker CJ, Raskino C, McKinney RE, Petrie B, Fowler MG, et al, for the AIDS Clinical Trials Group (ACTG) Study 152 Team. Zidovudine, didanosine, or both as the initial treatment for symptomatic HIV-infected children. N Engl J Med 1997;336:1704-12.
43. Tokars JI, Marcus R, Culver DH, Schable CA, McKibben PS, Bandea CI, et al. Surveillance of HIV infection and zidovudine use among health care workers after occupational exposure to HIV-infected blood. Ann Intern Med 1993;118:913-9.
44. Henderson DK, Fahey BJ, Willy M, Schmitt JM, Carey K, Koziol DE, et al. Risk for occupational transmission of human immunodeficiency virus type 1 (HIV-1) associated with clinical exposures. A prospective evaluation. Ann Intern Med 1990;113:740-6.
45. US Centers for Disease Control and Prevention. Update: provisional recommendations for chemoprophylaxis after occupational exposure to human immunodeficiency virus. MMWR 1996;45:468-72.
46. US Centers for Disease Control and Prevention. Update: case-control study of HIV seroconversion in health-care workers after percutaneous exposure to HIV-infected blood - France, United Kingdom, and United States, January 1988-August 1994. MMWR 1995;44:929-33.
47. Katz MH, Gerberding JL. Postexposure treatment of people exposed to the human immunodeficiency virus through sexual contact or injection-drug use. N Engl J Med 1997;336:1097-100.
48. Gerberding JL. Prophylaxis for occupational exposure to HIV. Ann Intern Med 1996;125:497-501.
49. Patrick DM. HIV postexposure prophylaxis: new recommendations. CMAJ 1997;156:233.
50. Kitahata MM, Koepsell TD, Deyo RA, Maxwell CL, Dodge WT, Wagner EH. Physicians' experience with the acquired immunodeficiency syndrome as a factor in patients' survival. N Engl J Med 1996;334:701-6.
51. BHIVA Guidelines Coordinating Committee. British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals. Lancet 1997;349:1086-92.
52. Carpenter CCJ, Fischl MA, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein DA, et al. Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA Panel. JAMA 1997;277:1962-9.
53. Panel on Clinical Practices for Treatment of HIV Infection. Guidelines for the use of antiretroviral agents in HIV infected adults and adolescents. Washington: US Department of Health and Human Services; 1997 Nov 5. Available: www.hivatis.org (accessed 1998 Jan 23).
54. Working Group on Antiretroviral Therapy and Medical Management of HIV Infected Children. Revised guidelines for the use of antiretroviral agents in pediatric HIV infection. Health Resources and Services Administration; 1997 Dec 9. Available: www.hivatis.org (accessed 1998 Jan 23).
55. U.S. Public Health Service Task Force recommendations for use of antiretroviral drugs during pregnancy for maternal health and reduction of perinatal transmission of human immunodeficiency virus type 1 in the United States. US Public Health Service; 1997 Dec 9. Available: www.hivatis.org (accessed 1998 Jan 23).